Compare Boston Scientific Corporation (BSX) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs iShares MSCI Indonesia ETF — how do they compare? Boston Scientific Corporation trades at $42.65 (market cap $66.37B), while iShares MSCI Indonesia ETF trades at $12. The key difference: iShares MSCI Indonesia ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | EIDO | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | — |
52-Week High | $108.14 | $19.22 |
52-Week Low | $42.63 | $10.80 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
EIDO, the iShares MSCI Indonesia ETF, trades at $11.98, up 1.1% on the day, but technical indicators signal a bearish trend with moving averages and RSI_6 suggesting caution. Key financial ratios are unavailable, but recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal program and central bank rate hikes to support the rupiah. The ETF's dividend dropped 27% in 2025, indicating potential income instability for investors.
The outlook for EIDO is mixed, with opportunities from Indonesia's GDP growth potential but risks from currency volatility and dividend cuts. Investors face headwinds from bearish technical signals and macroeconomic pressures, requiring careful assessment of emerging market exposure amid fluctuating sentiment and limited fundamental data.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
